BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30987640)

  • 21. Periostin Mediates TGF-β-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells.
    Hu Q; Tong S; Zhao X; Ding W; Gou Y; Xu K; Sun C; Xia G
    Cell Physiol Biochem; 2015; 36(2):799-809. PubMed ID: 26021267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
    Nam RK; Benatar T; Wallis CJ; Amemiya Y; Yang W; Garbens A; Naeim M; Sherman C; Sugar L; Seth A
    Prostate; 2016 Jul; 76(10):869-84. PubMed ID: 26990571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance.
    Liu CH; Tang WC; Sia P; Huang CC; Yang PM; Wu MH; Lai IL; Lee KH
    Int J Med Sci; 2015; 12(1):63-71. PubMed ID: 25552920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
    Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
    Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
    Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
    PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The up-regulation of long non-coding RNA CCAT2 indicates a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition.
    Zheng J; Zhao S; He X; Zheng Z; Bai W; Duan Y; Cheng S; Wang J; Liu X; Zhang G
    Biochem Biophys Res Commun; 2016 Nov; 480(4):508-514. PubMed ID: 27558961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.
    Li H; Kim C; Liu W; Zhu J; Chin K; Rodriguez-Canales J; Rodgers GP
    Int J Cancer; 2020 Mar; 146(5):1346-1358. PubMed ID: 31241767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NEDD9 crucially regulates TGF-β-triggered epithelial-mesenchymal transition and cell invasion in prostate cancer cells: involvement in cancer progressiveness.
    Morimoto K; Tanaka T; Nitta Y; Ohnishi K; Kawashima H; Nakatani T
    Prostate; 2014 Jun; 74(8):901-10. PubMed ID: 24728978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization.
    Cai G; Wu D; Wang Z; Xu Z; Wong KB; Ng CF; Chan FL; Yu S
    Oncogene; 2017 Jan; 36(4):546-558. PubMed ID: 27321179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long non-coding RNA ATB promotes growth and epithelial-mesenchymal transition and predicts poor prognosis in human prostate carcinoma.
    Xu S; Yi XM; Tang CP; Ge JP; Zhang ZY; Zhou WQ
    Oncol Rep; 2016 Jul; 36(1):10-22. PubMed ID: 27176634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RSPO3 expands intestinal stem cell and niche compartments and drives tumorigenesis.
    Hilkens J; Timmer NC; Boer M; Ikink GJ; Schewe M; Sacchetti A; Koppens MAJ; Song JY; Bakker ERM
    Gut; 2017 Jun; 66(6):1095-1105. PubMed ID: 27511199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.
    Gerke TA; Martin NE; Ding Z; Nuttall EJ; Stack EC; Giovannucci E; Lis RT; Stampfer MJ; Kantoff PW; Parmigiani G; Loda M; Mucci LA
    Prostate; 2015 Dec; 75(16):1926-33. PubMed ID: 26469352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
    Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
    J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SNAIL transcription factor increases the motility and invasive capacity of prostate cancer cells.
    Osorio LA; Farfán NM; Castellón EA; Contreras HR
    Mol Med Rep; 2016 Jan; 13(1):778-86. PubMed ID: 26648419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. R-spondin3 Is Associated with Basal-Progenitor Behavior in Normal and Tumor Mammary Cells.
    Tocci JM; Felcher CM; García Solá ME; Goddio MV; Zimberlin MN; Rubinstein N; Srebrow A; Coso OA; Abba MC; Meiss RP; Kordon EC
    Cancer Res; 2018 Aug; 78(16):4497-4511. PubMed ID: 29748375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.
    Bloom JE; McNeel DG
    Oncotarget; 2016 Aug; 7(32):50997-51011. PubMed ID: 27276714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion.
    Brown-Clay JD; Shenoy DN; Timofeeva O; Kallakury BV; Nandi AK; Banerjee PP
    Oncotarget; 2015 Jun; 6(17):15594-609. PubMed ID: 25909225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.